{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:28:39Z","timestamp":1784147319728,"version":"3.55.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Zinc-\u03b1<jats:sub>2<\/jats:sub>-glycoprotein (ZAG) has recently been characterized as a potent metabolic regulator. However, the effects of anti-diabetic agents on circulating ZAG levels in humans remain largely unknown. To explore the possible mechanisms by which the dipeptidyl peptidase-IV (DPP-IV) inhibitor improves insulin resistance, we investigated the effect of sitagliptin, a DPP-IV inhibitor, on circulating cytokine levels in newly diagnosed type 2 diabetes (nT2DM) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design and methods<\/jats:title><jats:p>A subset of 141 subjects with nT2DM were assigned to receive placebo (<jats:italic>n<\/jats:italic>=47) or sitagliptin (<jats:italic>n<\/jats:italic>=94) for 3 months. Before and after treatment, subjects received a 75\u200ag oral glucose tolerance test, euglycemic-hyperinsulinemic clamp (EHC), and measurement of ZAG and adiponectin (ADI) concentrations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Circulating ZAG levels were lower in nT2DM than in control individuals (<jats:italic>P<\/jats:italic>&lt;0.01). After 3 months of sitagliptin treatment, HbA1c, fasting plasma glucose, postprandial glucose, 2-h insulin after glucose overload, triglycerides, and homeostasis model assessment of insulin resistance (HOMA-IR) were decreased significantly compared with pre-treatment (<jats:italic>P<\/jats:italic>&lt;0.05 or<jats:italic>P<\/jats:italic>&lt;0.01), whereas the glucose infusion rate during the stable period of the clamp (<jats:italic>M<\/jats:italic>values) during EHC were significantly increased (<jats:italic>P<\/jats:italic>&lt;0.01). In addition, circulating ZAG and ADI concentrations were significantly increased along with improved glucose metabolism and insulin sensitivity compared with pre-treatment (both<jats:italic>P<\/jats:italic>&lt;0.01) and the change of ZAG (\u0394ZAG) was positively associated with \u0394ADI, \u0394HOMA-IR, \u0394BMI, \u0394fasting insulin and negatively associated with \u0394 tumor necrosis factor-\u03b1 (TNF-\u03b1). Furthermore, sitagliptin treatment resulted in significantly lowered plasma TNF-\u03b1 level (<jats:italic>P<\/jats:italic>&lt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A low level of circulating ZAG is associated with insulin resistance and sitagliptin treatment significantly increases circulating ZAG levels. These observations have implications in relation to the mode of action of the DPP-IV inhibitor as an insulin sensitizing agent.<\/jats:p><\/jats:sec>","DOI":"10.1530\/eje-15-0637","type":"journal-article","created":{"date-parts":[[2015,12,11]],"date-time":"2015-12-11T13:13:34Z","timestamp":1449839614000},"page":"147-155","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":30,"title":["Effects of sitagliptin on circulating zinc-\u03b12-glycoprotein levels in newly diagnosed type 2 diabetes patients: a randomized trial"],"prefix":"10.1093","volume":"174","author":[{"given":"Mingyuan","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zerong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengliu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvest F","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gangyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2015120919143155000_174.2.147.1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0395"},{"key":"2015120919143155000_174.2.147.2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.254"},{"key":"2015120919143155000_174.2.147.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2005.02.023"},{"key":"2015120919143155000_174.2.147.4","doi-asserted-by":"crossref","unstructured":"Burgi W Schmid K . Preparation and properties of Zn-\u03b1 2-glycoprotein of normal human plasma. Journal of Biological Chemistry 1961 236 1066\u20131074.","DOI":"10.1016\/S0021-9258(18)64243-7"},{"key":"2015120919143155000_174.2.147.5","doi-asserted-by":"publisher","DOI":"10.1177\/39.9.1918940"},{"key":"2015120919143155000_174.2.147.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.11.042"},{"key":"2015120919143155000_174.2.147.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308647100"},{"key":"2015120919143155000_174.2.147.8","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0058"},{"key":"2015120919143155000_174.2.147.9","doi-asserted-by":"crossref","unstructured":"Eckardt K Schober A Platzbecker B Mracek T Bing C Trayhurn P Eckel J . The adipokine zinc-\u03b12-glycoprotein activates AMP kinase in human primary skeletal muscle cells. Archives of Physiology and Biochemistry 2011 117 88\u201393. (doi:10.3109\/13813455.2011.560950).","DOI":"10.3109\/13813455.2011.560950"},{"key":"2015120919143155000_174.2.147.10","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0940"},{"key":"2015120919143155000_174.2.147.11","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S"},{"key":"2015120919143155000_174.2.147.12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2466"},{"key":"2015120919143155000_174.2.147.13","doi-asserted-by":"crossref","unstructured":"Jia Y Yuan L Hu W Luo Y Suo L Yang M Chen S Wang Y Liu H Yang G . Zinc-finger BED domain-containing 3 (Zbed3) is a novel secreted protein associated with insulin resistance in humans. Journal of Internal Medicine 2014 275 522\u2013533. (doi:10.1111\/joim.12170).","DOI":"10.1111\/joim.12170"},{"key":"2015120919143155000_174.2.147.14","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051561"},{"key":"2015120919143155000_174.2.147.15","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.920009"},{"key":"2015120919143155000_174.2.147.16","doi-asserted-by":"crossref","unstructured":"Goring S Hawkins N Wygant G Roudaut M Townsend R Wood I Barnett AH . Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes, Obesity & Metabolism 2014 16 433\u2013442. (doi:10.1111\/dom.12239).","DOI":"10.1111\/dom.12239"},{"key":"2015120919143155000_174.2.147.17","doi-asserted-by":"crossref","unstructured":"Schernthaner G Barnett AH Patel S Hehnke U von Eynatten M Woerle HJ . Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged \u226565 years. Diabetes, Obesity & Metabolism 2014 16 1078\u20131086. (doi:10.1111\/dom.12321).","DOI":"10.1111\/dom.12321"},{"key":"2015120919143155000_174.2.147.18","doi-asserted-by":"crossref","unstructured":"Yale JF Bakris G Cariou B Nieto J David-Neto E Yue D Wajs E Figueroa K Jiang J Law G . Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity & Metabolism 2014 16 1016\u20131027. (doi:10.1111\/dom.12348).","DOI":"10.1111\/dom.12348"},{"key":"2015120919143155000_174.2.147.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005892"},{"key":"2015120919143155000_174.2.147.20","doi-asserted-by":"crossref","unstructured":"Yang HK Kang B Lee SH Kim HS Yoon KH Cha BY Cho JH . Effects of 6-month sitagliptin treatment on insulin and glucagon responses in Korean patients with type 2 diabetes mellitus. Diabetes & Metabolism Journal 2015 39 335\u2013341. (doi:10.4093\/dmj.2015.39.4.335).","DOI":"10.4093\/dmj.2015.39.4.335"},{"key":"2015120919143155000_174.2.147.21","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.9.2677"},{"key":"2015120919143155000_174.2.147.22","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.8.1936"},{"key":"2015120919143155000_174.2.147.23","doi-asserted-by":"crossref","unstructured":"Fruhbeck G Gomez-Ambrosi J Muruzabal FJ Burrell MA . The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. American Journal of Physiology. Endocrinology and Metabolism 2001 280 E827\u2013E847.","DOI":"10.1152\/ajpendo.2001.280.6.E827"},{"key":"2015120919143155000_174.2.147.24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038744"},{"key":"2015120919143155000_174.2.147.25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255036"},{"key":"2015120919143155000_174.2.147.26","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.2.376"},{"key":"2015120919143155000_174.2.147.27","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.10.2968"},{"key":"2015120919143155000_174.2.147.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(03)00055-6"},{"key":"2015120919143155000_174.2.147.29","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0199"},{"key":"2015120919143155000_174.2.147.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.06.004"},{"key":"2015120919143155000_174.2.147.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2012.09.004"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/2\/147.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/174\/2\/147.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:33:08Z","timestamp":1676392388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/174\/2\/147\/6655501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":31,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.1530\/eje-15-0637","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}